CytoMed Therapeutics Limited
GDTCNASDAQHealthcare● Active
$1.07
$-0.09(-7.39%)
Market Cap$12601969
P/E Ratio—
52W High$3.68
52W Low$0.68
CytoMed Therapeutics Limited（GDTC）· 现金流量表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · GDTC · 截至 2026-06-10
财务报表
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($4.00M) | ($2.52M) | ($4.14M) | ($3.15M) | ($2.06M) |
| Depreciation & Amort. | $0.40M | $0.34M | $0.38M | $0.39M | $0.33M |
| Stock-Based Comp. | $0.69M | $0.00M | $0.00M | $0.00M | $0.00M |
| Change in Working Capital | ($0.49M) | ($0.08M) | ($0.01M) | ($0.15M) | ($0.43M) |
| Net Cash from Operations | ($3.70M) | ($2.71M) | ($3.54M) | ($1.40M) | ($1.72M) |
| Investing Activities | |||||
| Capital Expenditure | ($0.70M) | ($1.40M) | ($0.06M) | ($0.48M) | ($0.58M) |
| Purchases of Investments | $0.00M | $0.00M | ($2.73M) | $0.00M | ($0.24M) |
| Sales of Investments | $0.27M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Cash from Investing | $0.93M | $0.68M | ($2.79M) | ($0.48M) | ($0.83M) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Dividends Paid | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Debt Issued / Repaid | ($0.05M) | ($0.04M) | ($0.04M) | ($0.08M) | ($0.06M) |
| Net Cash from Financing | $0.21M | ($0.05M) | $10.80M | $0.97M | $4.18M |
| Free Cash Flow | |||||
| Free Cash Flow | ($4.40M) | ($4.11M) | ($3.60M) | ($1.88M) | ($2.30M) |
| FCF Margin %(computed) | — | — | -706.96% | -514.47% | — |
数据来源：Financial Modeling Prep · 最后更新：2026-06-10 · SGD · M
深入了解CytoMed Therapeutics Limited
关于CytoMed Therapeutics Limited（GDTC）现金流量表
CytoMed Therapeutics Limited 2025财年经营活动现金流($0.00B)，自由现金流($0.00B)（FCF利润率-1378.63%），资本支出($0.00B)。
常见问题
GDTC · 4 问CytoMed Therapeutics Limited 2025财年自由现金流($0.00B)，同比down7.1%。
GDTC free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10